拆解美国580亿美元减肥药市场:诺和诺德市占率达56.7%

格隆汇
Aug 06

据统计,美国的减肥药市场规模约为580亿美元。在美国,约有12%的成年人尝试过GLP-1药物,其中6%正在服用相关药物。

尽管品牌众多,但减肥药市场基本上由两家公司主导:丹麦的诺和诺德公司和美国的礼来公司。整体而言,诺和诺德的市占率达56.7%,高于礼来的43.3%。其中,诺和诺德的Ozempic占据31.5%的市场份额,为最畅销的减肥药物。其次是礼来的Mounjaro,占比达23.4%。剩余的市场份额则由两家公司旗下的其他品牌瓜分,包括Wegovy(16.5%)、Zepbound(11.6%)和Trulicity(8.4%)等。

责任编辑:安东

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10